rewirebio.iobenchmarks
Source

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML · Peer-reviewed

DOI: 10.1002/advs.202308243

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
Fragment coverage (fragment midpoint counts), open chromatin regions after PCA dimension reduction, SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9640 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin regions after PCA dimension reduction), pan-cancer vs healthy AUC
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9638 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin regions), pan-cancer vs healthy AUC
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9747 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)0.9772 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9778 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9631 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9967 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9988 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9638 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)0.8381 unitlessDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9470 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)0.8867 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9083 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9400 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9750 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)1.0000 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)0.7300 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)0.8850 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)0.7900 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)0.8683 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)0.8533 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9650 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9750 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)0.5658 fractionDELFI 2019 internally cross-validated cancer detection cohortcoverage (open chromatin), Cristiano cohort cross-validation
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (lung cancer vs healthy; independent validation)0.8397 unitlessMathios et al. 2021 independent lung cohort, 46 lung cancer and 385 healthy (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Mathios et al. independent dataset (LUNG)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (lung cancer vs healthy; independent validation)0.6522 fractionMathios et al. 2021 independent lung cohort, 46 lung cancer and 385 healthy (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Mathios et al. independent dataset (LUNG)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (lung cancer vs healthy; independent validation)0.4565 fractionMathios et al. 2021 independent lung cohort, 46 lung cancer and 385 healthy (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Mathios et al. independent dataset (LUNG)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (lung cancer vs non-cancer; independent validation)0.7305 unitlessMathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)0.5426 fractionMathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (lung cancer vs non-cancer; independent validation)0.2713 fractionMathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (liver cancer vs healthy; independent validation)0.7969 unitlessZhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (liver cancer vs healthy; independent validation)0.625 fractionZhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 95% specificity (liver cancer vs healthy; independent validation)0.125 fractionZhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC)
Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)0.9429 unitlessJiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)coverage (open chromatin), Jiang cohort liver cancer cross-validation
DELFI fragmentation profile, region definition of the original publication (5 mb bins), SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9575 unitlessDELFI 2019 internally cross-validated cancer detection cohortDELFI (region definition of the original publication), pan-cancer vs healthy AUC
Fragment 5' end motif (4-mer), open chromatin regions after PCA dimension reduction, SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9737 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin regions after PCA dimension reduction), pan-cancer vs healthy AUC
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9736 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin regions), pan-cancer vs healthy AUC
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9851 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)0.9900 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9997 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9627 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9977 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9890 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9736 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9544 unitlessDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9323 fractionDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)0.9550 fractionDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)1.0000 fractionDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)0.9200 fractionDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation
Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)1.0000 fractionDELFI 2019 internally cross-validated cancer detection cohortEDM (open chromatin), Cristiano cohort cross-validation

Claims

Statements this source supports, each with where in the source it was checked.

  • DELFI fragmentation profile: description: Description Short-to-long fragment ratios in 5 Mb bins. The method record names the feature definition, not an implementation. (Record description; cited Cristiano et al. 2019; Hou et al. reference 45)
  • Evidence summary: plasma ctDNA fragmentomics workflows: Summary Eight sources compare plasma cfDNA fragmentomic workflows on retrospective case-control cohorts. None is a prospective screening study and none measures clinical benefit. Cristiano et al. 2019, the DELFI developers, report 73% sensitivity (152 of 208 cancers) at a reported 98% specificity for DELFI in repeated cross-validation against 215 healthy individuals. Hou et al. 2024 re-implemented ten published fragmentation patterns and DELFI with one support vector machine each on the same cohort. They are independent of every pattern except IFS, which their corresponding author developed. In 10 x 10-fold cross-validation, pan-cancer AUC within open chromatin regions ranged from 0.8741 (fragment length) to 0.9736 (5' end motif), and their DELFI re-implementation reached 0.9575. Rankings changed on independent cohorts. On 46 lung cancers and 385 healthy individuals, with a model trained on 12 lung cancers, the end-motif model fell to AUC 0.5355 and sensitivity 0.0652 at 95% specificity, while fragment size distribution reached 0.9386 and 0.7174. Hou et al.'s supplementary pan-cancer and liver cancer sensitivities conflict with other tables of the same file and are not shown. Wang et al. 2026, the UNITE developers, stratified cancers by ichorCNA tumour fraction in pooled public and new 0.1x data that include samples of the DELFI and Jiang et al. cohorts used above. For cancers with an estimated tumour fraction of 3% or less, cross-validated AUC was 0.878 for all five features combined, 0.873 for fragment length, 0.857 for the SD of length counts, 0.736 for copy number, 0.715 for the C/T end-motif ratio and 0.651 for the short/long ratio, against 0.603 for a classifier using the ichorCNA tumour fraction alone, which detected 0.058 of these cancers at 95% specificity. For cancers with an estimated fraction above 3% and up to 10%, the ichorCNA classifier reached 0.983, above the combined model (0.962) and copy number alone (0.926). The extracted UNITE tables give sensitivity at a fixed specificity only for the ichorCNA comparator; the fragmentomic models' values are in a sheet not yet extracted. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, scored fragment length and fragment endpoint classifiers from 30x cfDNA whole-genome sequencing on the same CCGA substudy 1 participants as their methylation, copy-number and variant classifiers, at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers the fragment length classifier detected 29% (95% CI 25% to 34%) and the fragment endpoint classifier 18% (15% to 22%), against 34% for whole-genome methylation analysed double-blinded; both fragment classifiers were developed after the validation set had been unblinded, so these are not blinded validation results, and no tumour-fraction-stratified sensitivity is printed. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, computed fragmentomic features from cfMeDIP-seq reads, which are enriched for methylated fragments rather than drawn from whole-genome sequencing, and report means over 10 fold models. On an independent paired-end validation set, a fragment-ratio classifier reached AUC 0.848 and detected 0.533 of cancers at 99% specificity, and fragment ratios combined with methylation reached 0.954 and 0.766. The validation set has 17 healthy controls, so its 99% specificity allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in its sensitivities. Three of the five classifiers that include end motifs scored below AUC 0.5 there, which the authors attribute to healthy controls processed with a different laboratory protocol, so validation results for all five are not shown. Helzer et al. 2025 (Nature Communications) compared twelve fragmentomic metrics adapted to targeted exon panels, including the authors' own fragment-size entropy metrics, their combination and Griffin, with one classifier and shared folds, on plasma from patients with metastatic cancer. The healthy-versus-cancer one-vs-rest AUROC ranged from 0.835 (open-chromatin entropy) to 0.989 (first-exon depth) in a UW cohort of 404 cancers and 27 healthy donors, with Griffin at 0.944, and from 0.951 to 1.000 in public GRAIL panel data from 151 cancers and 47 healthy donors. In a developer comparison on 0.1x whole-genome sequencing (Cell Reports Medicine 2026), a fragment-level language model (Fragmentia-AI) reached AUC 0.9561 on a held-out set of unstated size, against 0.9209 to 0.935 for the developers' re-implementation of DELFI features and 0.881 to 0.8863 for Griffin features under three classifiers. The same company's whole-genome model (Molecular Biomedicine 2026), on an independent test cohort of 2,952 cancers and 3,044 non-cancer controls, reached AUC 0.910 for cancers with an ichorCNA tumour fraction below 3% and detected 0.46 of them at a cutoff set to 98% specificity in training (observed test specificity 0.97); among those low-fraction cancers it detected 0.391 at stage I/II (637 of 1,628) and 0.708 at stage III/IV (345 of 487). Its tumour-fraction strata are ichorCNA estimates, no comparator was run on its cohorts, and its training cohort has the same number of non-cancer controls (1,245) as the Cell Reports Medicine cohort, so the two studies may share samples. Three of these four studies report on their authors' own method, and in the fourth the authors' own entropy metrics are among those compared. Cohorts, feature implementations, classifiers and validation designs differ, so no value is comparable across sources. (amp-20261007-ctdna-fragmentomics-source: result amp-20261007-ctdna-fragmentomics-result; ctdnafrag-20261009-source-hou2024: Table 1, P24 and P44; ctdnafrag-20261009-source-hou2024-supporting-information: Table S3; ctdnafrag-20261009-source-wang2026-data-file-s2: STATS_xgb_x1-x6 and STATS_lr; ctdnafrag-20261009-source-wang2026: Results and Methods; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4c and Fig.4d; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Tables S1 and S2, 'Normal' columns; ctdnalit-20261011-helzer2025-source-article: Results P5-P8; ctdnalit-20261011-fragmentia2026-source-document-s1: Table S5; ctdnalit-20261011-fragmentia2026-source-article: Results P39-P44; ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Tables S1 and S4)
  • metric_implementation: ctdnafrag-20261009-protocol-hou2024-cristiano-pancan-cv-auc: Metric implementation Models were built with scikit-learn support vector machines with default parameters (XGBoost from the xgboost library for the comparison models); evaluation used 10 repeats of 10-fold cross-validation, with AUC and sensitivity at 95% and 85% specificity as the primary metrics. (Experimental Section 'Classification Model Construction' (P41) and 'Classification Model Evaluation' (P44-P45))
  • Relevance of ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity to "Select a plasma ctDNA fragmentomics detection workflow": Assessed by Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) (ctdnafrag-20261009-source-hou2024: Experimental Section P24-P45; ctdnafrag-20261009-source-hou2024-supporting-information: Tables S2 and S3)
  • Relevance of ctdnafrag-20261009-protocol-hou2024-cristiano-pancan-cv-auc to "Select a plasma ctDNA fragmentomics detection workflow": Assessed by Hou et al. 2024 pan-cancer vs healthy, Cristiano cohort, 10 x 10-fold cross-validation (Table 1 AUC) (ctdnafrag-20261009-source-hou2024: Table 1; Experimental Section P24, P29-P45)
  • Relevance of ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity to "Select a plasma ctDNA fragmentomics detection workflow": Assessed by Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2) (ctdnafrag-20261009-source-hou2024: Experimental Section P24-P45; ctdnafrag-20261009-source-hou2024-supporting-information: Tables S2 and S3)
  • Relevance of ctdnafrag-20261009-protocol-hou2024-mathios-independent to "Select a plasma ctDNA fragmentomics detection workflow": Assessed by Hou et al. 2024 independent validation, Mathios et al. independent lung cohort (Table S3) (ctdnafrag-20261009-source-hou2024: Experimental Section P24-P45; ctdnafrag-20261009-source-hou2024-supporting-information: Tables S2 and S3)
  • Relevance of ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent to "Select a plasma ctDNA fragmentomics detection workflow": Assessed by Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3) (ctdnafrag-20261009-source-hou2024: Experimental Section P24-P45; ctdnafrag-20261009-source-hou2024-supporting-information: Tables S2 and S3)
  • Relevance of ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent to "Select a plasma ctDNA fragmentomics detection workflow": Assessed by Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) (ctdnafrag-20261009-source-hou2024: Experimental Section P24-P45; ctdnafrag-20261009-source-hou2024-supporting-information: Tables S2 and S3)

Models, benchmarks and other records

Methods (11)

Configurations (25)

Protocols (6)

Datasets (4)

Evaluations (75)

Use cases (1)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

20 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Archive note
gzip -n -9 copy of the exact bytes in artifacts/hou2024-article.xml.gz (CC BY 4.0)
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Archive sha256
cac58f7aa06ffe301b4c4a7e6e7fb04ad85880ceba25bbc5b7d32e15cb0ec7a2
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_sha256

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact SHA-256
d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11321639/fullTextXML
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1002/advs.202308243
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Licence
CC-BY-4.0
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Media type
application/xml
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-10-09T20:27:02Z
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Source location
Full artifact bytes; per-result locators on each result
Source metadata
Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Original source ↗

No field-specific location recorded

Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Retrieved: 2026-10-09T20:27:02Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.source_locator

Source artifact SHA-256: d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Primary source retrieved and hashed for the plasma ctDNA fragmentomics use-case pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ctdnafrag-20261009-source-hou2024

areas
dna-genomes
contexts
clinical_research
url
https://doi.org/10.1002/advs.202308243
artifact url
https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11321639/fullTextXML
version
Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
retrieved at
2026-10-09T20:27:02Z
artifact sha256
d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70
doi
10.1002/advs.202308243
publication status
peer_reviewed
licence
CC-BY-4.0
media type
application/xml
source locator
Full artifact bytes; per-result locators on each result
archive sha256
cac58f7aa06ffe301b4c4a7e6e7fb04ad85880ceba25bbc5b7d32e15cb0ec7a2
archive note
gzip -n -9 copy of the exact bytes in artifacts/hou2024-article.xml.gz (CC BY 4.0)
Related records

    Suggest a correction